Drug
Interleukin-2 clinical trials
Also written IL-2 and Ro-236019.
- studies test it
- 213
- open now
- 32
- in phase 3
- 14
- first study started
- 1991
Keep track of what changes. Save the Interleukin-2 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
209 studies that test it; most in 2017 (12)
| Year | Studies |
|---|---|
| 1991 | 1 |
| 1993 | 3 |
| 1994 | 2 |
| 1995 | 2 |
| 1996 | 1 |
| 1997 | 2 |
| 1998 | 3 |
| 1999 | 3 |
| 2000 | 5 |
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 6 |
| 2004 | 8 |
| 2005 | 5 |
| 2006 | 7 |
| 2007 | 7 |
| 2008 | 1 |
| 2009 | 7 |
| 2010 | 2 |
| 2011 | 9 |
| 2012 | 10 |
| 2013 | 9 |
| 2014 | 9 |
| 2015 | 10 |
| 2016 | 10 |
| 2017 | 12 |
| 2018 | 5 |
| 2019 | 11 |
| 2020 | 9 |
| 2021 | 7 |
| 2022 | 12 |
| 2023 | 9 |
| 2024 | 7 |
| 2025 | 3 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 5
- Phase 1
- 71
- Phase 2
- 135
- Phase 3
- 14
- Phase 4
- 6
- No phase
- 12
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 38
Who runs them
Industry 13 · Other 200
Peking University People's Hospital (19) · H. Lee Moffitt Cancer Center and Research Institute (11) · National Institute of Allergy and Infectious Diseases (NIAID) (11) · Dana-Farber Cancer Institute (9) · National Cancer Institute (NCI) (9) · M.D. Anderson Cancer Center (8) · Masonic Cancer Center, University of Minnesota (5) · St. Jude Children's Research Hospital (4)
Often tested with
Tested in the same studies.
Cyclophosphamide (31) · Fludarabine (25) · Granulocyte-Macrophage Colony-Stimulating Factor (9) · Aldesleukin (7) · Ipilimumab (6) · Cisplatin (5) · Sirolimus (5) · Natural Killer Cell (4)
Studies
Open first, then newest update. How each study uses Interleukin-2 is read from its arms, and is right about nine times in ten.
Testing it · 213
- HS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01)RecruitingPhase 1Hangzhou Huasai Biomedicine Co., Ltd.NCT07105176Written as IL-2 (interleukin 2)
- A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02)RecruitingPhase 1Hangzhou Huasai Biomedicine Co., Ltd.NCT07830342Written as Interleukin 2 subcutaneous injection
- Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's DiseaseRecruitingPhase 1/2The Methodist Hospital Research InstituteNCT07651319Written as IL-2 (Aldesleukin)
- Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid TumorsRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT06047977Written as Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2
- Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum DisorderNot yet recruitingPhase 2Peking University People's HospitalNCT07809724Written as IL-2 (interleukin 2)
- Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseRecruitingPhase 1David Bartlett, MDNCT07192900Written as Interleukin-2
- A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PCRecruitingPhase 1/2CuraCell TX ABNCT07255664Written as Interleukin-2
- Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationRecruitingPhase 1Dana-Farber Cancer InstituteNCT06138587Written as Interleukin-2
- Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian CancerRecruitingPhase 1Dana-Farber Cancer InstituteNCT06321484Written as Interleukin 2
- Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T CellsRecruitingNot applicableCambridge University Hospitals NHS Foundation TrustNCT07610538Written as Interleukin-2 (Aldesleukin)
- Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary TumorsRecruitingPhase 1Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)NCT07443020Written as Interleukin-2 (IL-2)
- TIL Therapy in cSCC and MCCRecruitingPhase 2Karam Khaddour, MD, MSNCT07288073Written as Interleukin-2
- Venetoclax Combined With Azactidine in the Treatment of ALALRecruitingPhase 2Sheng-Li Xue, MDNCT05901974Written as azactidine
- Quadruple Immunotherapy for NeuroblastomaRecruitingPhase 2Hong Kong Children's HospitalNCT05754684Written as Interleukin-2
- Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV ViremiaNot yet recruitingPhase 2Peking University People's HospitalNCT06971913Written as Interleukin-2 (IL-2)
- Efficacy of Interleukin-2 in Triple Negative Breast CancerNot yet recruitingPhase 1/2Nova Scotia Health AuthorityNCT05821686Written as Human Interleukin-2 (IL-2) (Proleukin)
- Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid TumorsRecruitingEarly Phase 1Vall d'Hebron Institute of OncologyNCT05141474Written as Interleukin-2
- Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.RecruitingPhase 2Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNCT02919644Written as IL2
- A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.RecruitingPhase 2Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNCT04166006Written as Interleukin-2
- Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid TumorsRecruitingPhase 1Guangzhou FineImmune Biotechnology Co., LTD.NCT03891706Written as Interleukin-2
See all 213 studies that test Interleukin-2 →
Given in every arm · 96 — Interleukin-2 is usual care beside what is tested
- Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer(FASTIL-Renal01)RecruitingPhase 1Hangzhou Huasai Biomedicine Co., Ltd.NCT07770802Written as Interleukin 2 subcutaneous injection
- A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid TumorsRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06598371Written as Interleukin-2
- Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLCRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05681780Written as Interleukin-2 (IL2)
- Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver MetastasesNot yet recruitingPhase 1Vastra Gotaland RegionNCT05903937Written as Interleukin-2
- Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic MelanomaNot yet recruitingPhase 1Vastra Gotaland RegionNCT07183852Written as Interleukin-2
- Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)RecruitingPhase 1Paolo Caimi, MDNCT07225439Written as Interleukin-2
- Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 1Imugene LimitedNCT03666000Written as IL-2
- CIML NK Cells With Venetoclax for AMLRecruitingPhase 1Dana-Farber Cancer InstituteNCT06152809Written as Interleukin-2
- Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid TumorsRecruitingPhase 1/2Grit BiotechnologyNCT06144671Written as IL-2
- Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion.Not yet recruitingPhase 1/2Gritbio Medicine, Inc.NCT07766317Written as IL-2 and PD-1
- PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced MelanomaNot yet recruitingEarly Phase 1Abramson Cancer Center at Penn MedicineNCT07700121Written as IL-2
- Clinical Trial of CD40L-augmented TIL for Patients With Advanced MelanomaRecruitingPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT06961357Written as Interleukin-2
- Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCTRecruitingPhase 1/2Masonic Cancer Center, University of MinnesotaNCT07591649Written as IL-2
- NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid TumorsRecruitingPhase 1TCRCure Biopharma Ltd.NCT05881525Written as IL-2
- IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersRecruitingPhase 1/2Indapta Therapeutics, INC.NCT06119685Written as Interleukin-2
- Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid TumorsRecruitingPhase 1Guangzhou FineImmune Biotechnology Co., LTD.NCT06302062Written as IL-2
- TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast CancerRecruitingPhase 1/2Essen BiotechNCT06532812Written as Interleukin-2
- TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal CancerRecruitingPhase 1/2Essen BiotechNCT06532799Written as Interleukin-2
- TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and MeningiomasRecruitingPhase 1/2Essen BiotechNCT06640582Written as Interleukin-2
- Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum CancerRecruitingPhase 1/2Essen BiotechNCT06530303Written as Interleukin-2
Showing 20 of 96.
As the comparator · 5 — what is tested is compared with Interleukin-2
- Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)RecruitingPhase 2Vall d'Hebron Institute of OncologyNCT06630611Written as High dose IL-2
- Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.Active, not recruitingPhase 2Providence Health & ServicesNCT01416831Written as High-dose IL-2
- Natural Killer-cell Therapy for Acute Myeloid LeukemiaTerminatedPhase 1/2Radboud University Medical CenterNCT04347616Written as IL-2
- Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural EffusionStatus unknownNot applicablePeking Union Medical CollegeNCT04131231Written as recombinant human interleukin-2(rhIL-2)
- Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney CancerStatus unknownPhase 2University of AarhusNCT01274273Written as Interleukin-2
Codes
What other systems call Interleukin-2 · ClinicalTrials.gg INT007673
- MeSH (NLM) D007376Interleukin-2One source ClinicalTrials.gov
- UNII (FDA) FNO32LO217HUMAN INTERLEUKIN-2One source FDA
- NCI Thesaurus C587Recombinant Interleukin-2One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D007376 | Interleukin-2 | One source ClinicalTrials.gov |
| UNII (FDA) | FNO32LO217 | HUMAN INTERLEUKIN-2 | One source FDA |
| NCI Thesaurus | C587 | Recombinant Interleukin-2 | One source FDA |
Also registered as teceleukin (UNII H5ZRB188EI).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.